Literature DB >> 23405850

Clinical symptoms of psychotic episodes and 25-hydroxy vitamin D serum levels in black first-generation immigrants.

M-J Dealberto1.   

Abstract

OBJECTIVE: Dark-skinned immigrants have a higher risk for schizophrenia and other psychoses than other immigrants. The first British studies reported that first-generation immigrants (FGIs) from the Caribbean presented atypical psychoses. This study examines the characteristics of psychotic episodes in black FGIs to Canada.
METHOD: The charts of 18 FGIs from Africa and Haiti, extracted from a series of 20 black patients consecutively admitted to Psychiatry, were retrospectively reviewed regarding clinical features, diagnoses and vitamin D levels.
RESULTS: Young FGIs presented acute psychotic episodes with abrupt onset, florid positive symptoms, few negative symptoms and good evolution. The onset was more insidious in older FGIs. Overall, catatonia was very frequent (28%), and mood symptoms still more frequent (44%). No cognitive decline was observed during follow-up. Serum levels of 25-hydroxy vitamin D were in the insufficiency range. Supplementation at 1000 IU/day did not restore normal levels.
CONCLUSION: The clinical features of psychotic episodes in black FGIs are similar to those reported in dark-skinned FGIs to other countries. They are also observed in other immigrants and in non-immigrants. These atypical psychoses are possibly related to a recent vitamin D deficit. This hypothesis should be tested by clinical trials of sufficient vitamin D supplementation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute psychotic episodes; atypical psychosis; immigrants; schizophrenia; skin pigmentation; vitamin D

Mesh:

Substances:

Year:  2013        PMID: 23405850     DOI: 10.1111/acps.12086

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

Review 1.  Vitamin supplementation in the treatment of schizophrenia.

Authors:  Hannah E Brown; Joshua L Roffman
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

Review 2.  Associating schizophrenia, long non-coding RNAs and neurostructural dynamics.

Authors:  Veronica Merelo; Dante Durand; Adam R Lescallette; Kent E Vrana; L Elliot Hong; Mohammad Ali Faghihi; Alfredo Bellon
Journal:  Front Mol Neurosci       Date:  2015-09-30       Impact factor: 5.639

3.  Vitamin D Deficiency in Adult Patients with Schizophreniform and Autism Spectrum Syndromes: A One-Year Cohort Study at a German Tertiary Care Hospital.

Authors:  Dominique Endres; Rick Dersch; Oliver Stich; Armin Buchwald; Evgeniy Perlov; Bernd Feige; Simon Maier; Andreas Riedel; Ludger Tebartz van Elst
Journal:  Front Psychiatry       Date:  2016-10-06       Impact factor: 4.157

4.  Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients.

Authors:  Amir Ghaderi; Hamid Reza Banafshe; Naghmeh Mirhosseini; Mohamad Moradi; Mohammad-Amin Karimi; Fateme Mehrzad; Fereshteh Bahmani; Zatollah Asemi
Journal:  BMC Psychiatry       Date:  2019-02-21       Impact factor: 3.630

5.  Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Fiona Gaughran; Dominic Stringer; Michael Berk; Shubulade Smith; David Taylor; Eromona Whiskey; Sabine Landau; Robin Murray; Philip McGuire; Poonam Gardner-Sood; Gabriella Wojewodka; Simone Ciufolini; Harriet Jordan; Jessie Clarke; Lauren Allen; Amir Krivoy; Brendon Stubbs; Philippa Lowe; Maurice Arbuthnott; Shanaya Rathod; Andrew Boardman; Mudasir Firdosi; John J McGrath
Journal:  Trials       Date:  2020-01-06       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.